CD95 and Multidrug Resistance in Kidney Cancer
Author Information
Author(s): Ramp U, Dejosez M, Mahotka C, Czarnotta B, Kalinski T, Wenzel M, Lorenz I, Müller M, Krammer P, Gabbert H E, Gerharz C D
Primary Institution: Institute of Pathology, Heinrich Heine University
Hypothesis
The study investigates the role of the CD95 system in chemotherapy-induced apoptosis in renal cell carcinoma (RCC) cell lines.
Conclusion
The study found that while CD95 components are present in most RCC cell lines, the anticancer drugs topotecan and bleomycin do not effectively activate CD95-mediated apoptosis.
Supporting Evidence
- All RCC cell lines expressed CD95-receptor and -ligand.
- Agonistic anti-CD95 antibodies induced apoptosis in three out of four RCC cell lines.
- Topotecan and bleomycin led to significant dose-dependent reduction of cell number in all RCC cell lines.
- Both anticancer drugs induced upregulation of CD95 ligand expression in all cell lines.
Takeaway
Researchers looked at how kidney cancer cells respond to certain drugs and found that even though the cells have the tools to die, the drugs don't make them do it.
Methodology
The study analyzed four newly established RCC cell lines for CD95 receptor and ligand expression and their response to anticancer drugs.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website